世界の表皮水疱症治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Epidermolysis Bullosa Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4195 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、表皮水疱症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（EB-201、FCX-007、ICX-RHY、INM-750、その他）、用途別市場規模（診療所、病院、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・表皮水疱症治療薬の市場動向 ・企業の競争状況、市場シェア ・表皮水疱症治療薬の種類別市場規模と予測2016-2027（EB-201、FCX-007、ICX-RHY、INM-750、その他） ・表皮水疱症治療薬の用途別市場規模と予測2016-2027（診療所、病院、その他） ・表皮水疱症治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・表皮水疱症治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・表皮水疱症治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・表皮水疱症治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・表皮水疱症治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Birken AG、Fibrocell Science, Inc.、GlaxoSmithKline Plc、InMed Pharmaceuticals Inc.、Karus Therapeutics Limited、ProQR Therapeutics N.V.、RegeneRx Biopharmaceuticals, Inc.、Scioderm, Inc.、Stratatech Corporation、TWi Pharmaceuticals, Inc.、WAVE Life Sciences Ltd.） ・結論

Market Analysis and Insights: Global Epidermolysis Bullosa Therapeutics Market
The global Epidermolysis Bullosa Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Epidermolysis Bullosa Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Epidermolysis Bullosa Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Epidermolysis Bullosa Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Epidermolysis Bullosa Therapeutics market.

Global Epidermolysis Bullosa Therapeutics Scope and Market Size
Epidermolysis Bullosa Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Epidermolysis Bullosa Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
EB-201
FCX-007
ICX-RHY
INM-750
Others

Segment by Application
Clinic
Hospital
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Birken AG
Fibrocell Science, Inc.
GlaxoSmithKline Plc
InMed Pharmaceuticals Inc.
Karus Therapeutics Limited
ProQR Therapeutics N.V.
RegeneRx Biopharmaceuticals, Inc.
Scioderm, Inc.
Stratatech Corporation
TWi Pharmaceuticals, Inc.
WAVE Life Sciences Ltd.

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Epidermolysis Bullosa Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 EB-201
1.2.3 FCX-007
1.2.4 ICX-RHY
1.2.5 INM-750
1.2.6 Others
1.3 Market by Application
1.3.1 Global Epidermolysis Bullosa Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Epidermolysis Bullosa Therapeutics Market Perspective (2016-2027)
2.2 Epidermolysis Bullosa Therapeutics Growth Trends by Regions
2.2.1 Epidermolysis Bullosa Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Epidermolysis Bullosa Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Epidermolysis Bullosa Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Epidermolysis Bullosa Therapeutics Industry Dynamic
2.3.1 Epidermolysis Bullosa Therapeutics Market Trends
2.3.2 Epidermolysis Bullosa Therapeutics Market Drivers
2.3.3 Epidermolysis Bullosa Therapeutics Market Challenges
2.3.4 Epidermolysis Bullosa Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Epidermolysis Bullosa Therapeutics Players by Revenue
3.1.1 Global Top Epidermolysis Bullosa Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Epidermolysis Bullosa Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Epidermolysis Bullosa Therapeutics Revenue
3.4 Global Epidermolysis Bullosa Therapeutics Market Concentration Ratio
3.4.1 Global Epidermolysis Bullosa Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Epidermolysis Bullosa Therapeutics Revenue in 2020
3.5 Epidermolysis Bullosa Therapeutics Key Players Head office and Area Served
3.6 Key Players Epidermolysis Bullosa Therapeutics Product Solution and Service
3.7 Date of Enter into Epidermolysis Bullosa Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Epidermolysis Bullosa Therapeutics Breakdown Data by Type
4.1 Global Epidermolysis Bullosa Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Epidermolysis Bullosa Therapeutics Forecasted Market Size by Type (2022-2027)

5 Epidermolysis Bullosa Therapeutics Breakdown Data by Application
5.1 Global Epidermolysis Bullosa Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Epidermolysis Bullosa Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Epidermolysis Bullosa Therapeutics Market Size (2016-2027)
6.2 North America Epidermolysis Bullosa Therapeutics Market Size by Type
6.2.1 North America Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Epidermolysis Bullosa Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2027)
6.3 North America Epidermolysis Bullosa Therapeutics Market Size by Application
6.3.1 North America Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Epidermolysis Bullosa Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2027)
6.4 North America Epidermolysis Bullosa Therapeutics Market Size by Country
6.4.1 North America Epidermolysis Bullosa Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Epidermolysis Bullosa Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Epidermolysis Bullosa Therapeutics Market Size (2016-2027)
7.2 Europe Epidermolysis Bullosa Therapeutics Market Size by Type
7.2.1 Europe Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Epidermolysis Bullosa Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2027)
7.3 Europe Epidermolysis Bullosa Therapeutics Market Size by Application
7.3.1 Europe Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Epidermolysis Bullosa Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2027)
7.4 Europe Epidermolysis Bullosa Therapeutics Market Size by Country
7.4.1 Europe Epidermolysis Bullosa Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Epidermolysis Bullosa Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Type
8.2.1 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Application
8.3.1 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Region
8.4.1 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Epidermolysis Bullosa Therapeutics Market Size (2016-2027)
9.2 Latin America Epidermolysis Bullosa Therapeutics Market Size by Type
9.2.1 Latin America Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Epidermolysis Bullosa Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Epidermolysis Bullosa Therapeutics Market Size by Application
9.3.1 Latin America Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Epidermolysis Bullosa Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Epidermolysis Bullosa Therapeutics Market Size by Country
9.4.1 Latin America Epidermolysis Bullosa Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Epidermolysis Bullosa Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Type
10.2.1 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Application
10.3.1 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Country
10.4.1 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Birken AG
11.1.1 Birken AG Company Details
11.1.2 Birken AG Business Overview
11.1.3 Birken AG Epidermolysis Bullosa Therapeutics Introduction
11.1.4 Birken AG Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.1.5 Birken AG Recent Development
11.2 Fibrocell Science, Inc.
11.2.1 Fibrocell Science, Inc. Company Details
11.2.2 Fibrocell Science, Inc. Business Overview
11.2.3 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Introduction
11.2.4 Fibrocell Science, Inc. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.2.5 Fibrocell Science, Inc. Recent Development
11.3 GlaxoSmithKline Plc
11.3.1 GlaxoSmithKline Plc Company Details
11.3.2 GlaxoSmithKline Plc Business Overview
11.3.3 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Introduction
11.3.4 GlaxoSmithKline Plc Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.3.5 GlaxoSmithKline Plc Recent Development
11.4 InMed Pharmaceuticals Inc.
11.4.1 InMed Pharmaceuticals Inc. Company Details
11.4.2 InMed Pharmaceuticals Inc. Business Overview
11.4.3 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Introduction
11.4.4 InMed Pharmaceuticals Inc. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.4.5 InMed Pharmaceuticals Inc. Recent Development
11.5 Karus Therapeutics Limited
11.5.1 Karus Therapeutics Limited Company Details
11.5.2 Karus Therapeutics Limited Business Overview
11.5.3 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Introduction
11.5.4 Karus Therapeutics Limited Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.5.5 Karus Therapeutics Limited Recent Development
11.6 ProQR Therapeutics N.V.
11.6.1 ProQR Therapeutics N.V. Company Details
11.6.2 ProQR Therapeutics N.V. Business Overview
11.6.3 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Introduction
11.6.4 ProQR Therapeutics N.V. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.6.5 ProQR Therapeutics N.V. Recent Development
11.7 RegeneRx Biopharmaceuticals, Inc.
11.7.1 RegeneRx Biopharmaceuticals, Inc. Company Details
11.7.2 RegeneRx Biopharmaceuticals, Inc. Business Overview
11.7.3 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Introduction
11.7.4 RegeneRx Biopharmaceuticals, Inc. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.7.5 RegeneRx Biopharmaceuticals, Inc. Recent Development
11.8 Scioderm, Inc.
11.8.1 Scioderm, Inc. Company Details
11.8.2 Scioderm, Inc. Business Overview
11.8.3 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Introduction
11.8.4 Scioderm, Inc. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.8.5 Scioderm, Inc. Recent Development
11.9 Stratatech Corporation
11.9.1 Stratatech Corporation Company Details
11.9.2 Stratatech Corporation Business Overview
11.9.3 Stratatech Corporation Epidermolysis Bullosa Therapeutics Introduction
11.9.4 Stratatech Corporation Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.9.5 Stratatech Corporation Recent Development
11.10 TWi Pharmaceuticals, Inc.
11.10.1 TWi Pharmaceuticals, Inc. Company Details
11.10.2 TWi Pharmaceuticals, Inc. Business Overview
11.10.3 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Introduction
11.10.4 TWi Pharmaceuticals, Inc. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.10.5 TWi Pharmaceuticals, Inc. Recent Development
11.11 WAVE Life Sciences Ltd.
11.11.1 WAVE Life Sciences Ltd. Company Details
11.11.2 WAVE Life Sciences Ltd. Business Overview
11.11.3 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Introduction
11.11.4 WAVE Life Sciences Ltd. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021)
11.11.5 WAVE Life Sciences Ltd. Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Epidermolysis Bullosa Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of EB-201
Table 3. Key Players of FCX-007
Table 4. Key Players of ICX-RHY
Table 5. Key Players of INM-750
Table 6. Key Players of Others
Table 7. Global Epidermolysis Bullosa Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Epidermolysis Bullosa Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Epidermolysis Bullosa Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Epidermolysis Bullosa Therapeutics Market Share by Regions (2016-2021)
Table 11. Global Epidermolysis Bullosa Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Epidermolysis Bullosa Therapeutics Market Share by Regions (2022-2027)
Table 13. Epidermolysis Bullosa Therapeutics Market Trends
Table 14. Epidermolysis Bullosa Therapeutics Market Drivers
Table 15. Epidermolysis Bullosa Therapeutics Market Challenges
Table 16. Epidermolysis Bullosa Therapeutics Market Restraints
Table 17. Global Epidermolysis Bullosa Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Epidermolysis Bullosa Therapeutics Market Share by Players (2016-2021)
Table 19. Global Top Epidermolysis Bullosa Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Epidermolysis Bullosa Therapeutics as of 2020)
Table 20. Ranking of Global Top Epidermolysis Bullosa Therapeutics Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Epidermolysis Bullosa Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Epidermolysis Bullosa Therapeutics Product Solution and Service
Table 24. Date of Enter into Epidermolysis Bullosa Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Type (2016-2021)
Table 28. Global Epidermolysis Bullosa Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Epidermolysis Bullosa Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Application (2016-2021)
Table 32. Global Epidermolysis Bullosa Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Epidermolysis Bullosa Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Epidermolysis Bullosa Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Epidermolysis Bullosa Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Epidermolysis Bullosa Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Epidermolysis Bullosa Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Epidermolysis Bullosa Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Epidermolysis Bullosa Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Epidermolysis Bullosa Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Epidermolysis Bullosa Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Epidermolysis Bullosa Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Epidermolysis Bullosa Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Epidermolysis Bullosa Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 64. Birken AG Company Details
Table 65. Birken AG Business Overview
Table 66. Birken AG Epidermolysis Bullosa Therapeutics Product
Table 67. Birken AG Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021) & (US$ Million)
Table 68. Birken AG Recent Development
Table 69. Fibrocell Science, Inc. Company Details
Table 70. Fibrocell Science, Inc. Business Overview
Table 71. Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Product
Table 72. Fibrocell Science, Inc. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021) & (US$ Million)
Table 73. Fibrocell Science, Inc. Recent Development
Table 74. GlaxoSmithKline Plc Company Details
Table 75. GlaxoSmithKline Plc Business Overview
Table 76. GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Product
Table 77. GlaxoSmithKline Plc Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021) & (US$ Million)
Table 78. GlaxoSmithKline Plc Recent Development
Table 79. InMed Pharmaceuticals Inc. Company Details
Table 80. InMed Pharmaceuticals Inc. Business Overview
Table 81. InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Product
Table 82. InMed Pharmaceuticals Inc. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021) & (US$ Million)
Table 83. InMed Pharmaceuticals Inc. Recent Development
Table 84. Karus Therapeutics Limited Company Details
Table 85. Karus Therapeutics Limited Business Overview
Table 86. Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Product
Table 87. Karus Therapeutics Limited Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021) & (US$ Million)
Table 88. Karus Therapeutics Limited Recent Development
Table 89. ProQR Therapeutics N.V. Company Details
Table 90. ProQR Therapeutics N.V. Business Overview
Table 91. ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Product
Table 92. ProQR Therapeutics N.V. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021) & (US$ Million)
Table 93. ProQR Therapeutics N.V. Recent Development
Table 94. RegeneRx Biopharmaceuticals, Inc. Company Details
Table 95. RegeneRx Biopharmaceuticals, Inc. Business Overview
Table 96. RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product
Table 97. RegeneRx Biopharmaceuticals, Inc. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021) & (US$ Million)
Table 98. RegeneRx Biopharmaceuticals, Inc. Recent Development
Table 99. Scioderm, Inc. Company Details
Table 100. Scioderm, Inc. Business Overview
Table 101. Scioderm, Inc. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021) & (US$ Million)
Table 102. Scioderm, Inc. Recent Development
Table 103. Stratatech Corporation Company Details
Table 104. Stratatech Corporation Business Overview
Table 105. Stratatech Corporation Epidermolysis Bullosa Therapeutics Product
Table 106. Stratatech Corporation Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021) & (US$ Million)
Table 107. Stratatech Corporation Recent Development
Table 108. TWi Pharmaceuticals, Inc. Company Details
Table 109. TWi Pharmaceuticals, Inc. Business Overview
Table 110. TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product
Table 111. TWi Pharmaceuticals, Inc. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021) & (US$ Million)
Table 112. TWi Pharmaceuticals, Inc. Recent Development
Table 113. WAVE Life Sciences Ltd. Company Details
Table 114. WAVE Life Sciences Ltd. Business Overview
Table 115. WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Product
Table 116. WAVE Life Sciences Ltd. Revenue in Epidermolysis Bullosa Therapeutics Business (2016-2021) & (US$ Million)
Table 117. WAVE Life Sciences Ltd. Recent Development
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Epidermolysis Bullosa Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. EB-201 Features
Figure 3. FCX-007 Features
Figure 4. ICX-RHY Features
Figure 5. INM-750 Features
Figure 6. Others Features
Figure 7. Global Epidermolysis Bullosa Therapeutics Market Share by Application: 2020 VS 2027
Figure 8. Clinic Case Studies
Figure 9. Hospital Case Studies
Figure 10. Others Case Studies
Figure 11. Epidermolysis Bullosa Therapeutics Report Years Considered
Figure 12. Global Epidermolysis Bullosa Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Epidermolysis Bullosa Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Epidermolysis Bullosa Therapeutics Market Share by Regions: 2020 VS 2027
Figure 15. Global Epidermolysis Bullosa Therapeutics Market Share by Regions (2022-2027)
Figure 16. Global Epidermolysis Bullosa Therapeutics Market Share by Players in 2020
Figure 17. Global Top Epidermolysis Bullosa Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Epidermolysis Bullosa Therapeutics as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Epidermolysis Bullosa Therapeutics Revenue in 2020
Figure 19. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Type (2016-2021)
Figure 20. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Type (2022-2027)
Figure 21. North America Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Epidermolysis Bullosa Therapeutics Market Share by Type (2016-2027)
Figure 23. North America Epidermolysis Bullosa Therapeutics Market Share by Application (2016-2027)
Figure 24. North America Epidermolysis Bullosa Therapeutics Market Share by Country (2016-2027)
Figure 25. United States Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Epidermolysis Bullosa Therapeutics Market Share by Type (2016-2027)
Figure 29. Europe Epidermolysis Bullosa Therapeutics Market Share by Application (2016-2027)
Figure 30. Europe Epidermolysis Bullosa Therapeutics Market Share by Country (2016-2027)
Figure 31. Germany Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Epidermolysis Bullosa Therapeutics Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Epidermolysis Bullosa Therapeutics Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Epidermolysis Bullosa Therapeutics Market Share by Region (2016-2027)
Figure 41. China Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Epidermolysis Bullosa Therapeutics Market Share by Type (2016-2027)
Figure 49. Latin America Epidermolysis Bullosa Therapeutics Market Share by Application (2016-2027)
Figure 50. Latin America Epidermolysis Bullosa Therapeutics Market Share by Country (2016-2027)
Figure 51. Mexico Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Epidermolysis Bullosa Therapeutics Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Epidermolysis Bullosa Therapeutics Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Epidermolysis Bullosa Therapeutics Market Share by Country (2016-2027)
Figure 57. Turkey Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Epidermolysis Bullosa Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Birken AG Revenue Growth Rate in Epidermolysis Bullosa Therapeutics Business (2016-2021)
Figure 61. Fibrocell Science, Inc. Revenue Growth Rate in Epidermolysis Bullosa Therapeutics Business (2016-2021)
Figure 62. GlaxoSmithKline Plc Revenue Growth Rate in Epidermolysis Bullosa Therapeutics Business (2016-2021)
Figure 63. InMed Pharmaceuticals Inc. Revenue Growth Rate in Epidermolysis Bullosa Therapeutics Business (2016-2021)
Figure 64. Karus Therapeutics Limited Revenue Growth Rate in Epidermolysis Bullosa Therapeutics Business (2016-2021)
Figure 65. ProQR Therapeutics N.V. Revenue Growth Rate in Epidermolysis Bullosa Therapeutics Business (2016-2021)
Figure 66. RegeneRx Biopharmaceuticals, Inc. Revenue Growth Rate in Epidermolysis Bullosa Therapeutics Business (2016-2021)
Figure 67. Scioderm, Inc. Revenue Growth Rate in Epidermolysis Bullosa Therapeutics Business (2016-2021)
Figure 68. Stratatech Corporation Revenue Growth Rate in Epidermolysis Bullosa Therapeutics Business (2016-2021)
Figure 69. TWi Pharmaceuticals, Inc. Revenue Growth Rate in Epidermolysis Bullosa Therapeutics Business (2016-2021)
Figure 70. WAVE Life Sciences Ltd. Revenue Growth Rate in Epidermolysis Bullosa Therapeutics Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed

---